Stock & Company Details
Apimeds Pharmaceuticals US $APUS
Price:
N/A
N/A
N/A
$3.2M
52 Week High:
N/A
10 Day Average Volume:
N/A
-0.27
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
N/A
APUS technical indicators
Latest Apimeds Pharmaceuticals US (APUS) indicator readings as of 2026-11-19.
APUS's 14-day RSI is 29.6, in oversold territory. ADX reads 13.1, indicating a range-bound market rather than a trend. MACD (12, 26, 9) is -0.49, below the zero line.
Overview
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Finance Bot
Ask your questions
Start by typing a question below.